jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-2-65-72jofin-1354Research ArticleОбзорReviewВзаимосвязь между вирусом SARS-COV-2 и аутоиммунными неврологическими заболеваниямиRelationship between SARS-COV-2 And autoimmune neurological diseasesВласенкоА. И.VlasenkoA. I.

Власенко Анастасия Игоревна – медицинская сестра неврологического отделения; тел.: 8(812)670-30-03(001649)

Санкт-Петербург

Saint-Petersburg

nastya-vlasenko@inbox.ruПортикО. А.PortikO. A.

Портик Ольга Александровна – ассистент кафедры неврологии и психиатрии с клиникой ИМО; к.м.н.; тел.: +7-921-411-48-59

Санкт-Петербург

Saint-Petersburg

olgaportik@gmail.comБисагаГ. Н.BisagaG. N.

Бисага Геннадий Николаевич – профессор кафедры неврологии и психиатрии с клиникой ИМО; д.м.н., профессор; тел.: 8(812)670-30-03(001649)

Санкт-Петербург

Saint-Petersburg

bisaga@yandex.ruТопузоваМ. П.TopuzovaM. P.

Топузова Мария Петровна – доцент кафедры неврологии и психиатрии с клиникой ИМО; к.м.н., доцент; тел.: 8(812)670-30-03 (001649)

Санкт-Петербург

Saint-Petersburg

topuzova_mp@almazovcentre.ruМалькоВ. А.MalkoV. A.

Малько Валерия Алексеевна – аспирант, старший лаборант кафедры неврологии и психиатрии с клиникой ИМО; тел.: 8(812)670-30-03(001649)

Санкт-Петербург

Saint-Petersburg

mdmalkovaleriya@gmail.comИсабековаП. Ш.IsabekovaP. Sh.

Исабекова Патимат Шамильевна – аспирант, старший лаборант кафедры неврологии и психиатрии с клиникой ИМО; тел.: 8(812)670-30-03(001649)

Санкт-Петербург

Saint-Petersburg

isabekova_p@mail.ruСкрипченкоН. В.SkripchenkoN. V.

Скрипченко Наталья Викторовна – заместитель директора по научной работе; заведующая кафедрой инфекционных заболеваний у детей ФП и ДПО; д.м.н., профессор, заслуженный деятель науки Российской Федерации; тел.: 8(812) 234-10-38

Санкт-Петербург

Saint-Petersburg

snv@niidi.ruАлексееваТ. М.AlekseevaT. M.

Алексеева Татьяна Михайловна – заведующая кафедрой неврологии и психиатрии с клиникой ИМО; д.м.н., доцент; тел.: 8(812)670-30-03 (001745)

Санкт-Петербург

Saint-Petersburg

alekseeva_tm@almazovcentre.ruНациональный медицинский исследовательский центр имени B.A. АлмaзoвaРоссияNational Medical Research Center named after V.A. AlmazovRussian FederationДетский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университетРоссияChildren’s Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical UniversityRussian Federation2022130720221426572Copyright © Власенко А.И., Портик О.А., Бисага Г.Н., Топузова М.П., Малько В.А., Исабекова П.Ш., Скрипченко Н.В., Алексеева Т.М., 20222022Власенко А.И., Портик О.А., Бисага Г.Н., Топузова М.П., Малько В.А., Исабекова П.Ш., Скрипченко Н.В., Алексеева Т.М.Vlasenko A.I., Portik O.A., Bisaga G.N., Topuzova M.P., Malko V.A., Isabekova P.S., Skripchenko N.V., Alekseeva T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1354

С начала массового распространения инфекции, вызванной вирусом SARS-CoV-2, возросло количество сообщений об увеличении частоты аутоиммунных неврологических расстройств. Предполагается, что подобное повышение уровня заболеваемости может возникать вследствие аномального иммуноопосредованного ответа организма на патогенное воздействие SARS-CoV-2. В данной статье рассматривается возможность влияния вируса SARS-CoV-2 на возникновение и обострение течения аутоиммунных неврологических расстройств, обсуждаются возможные патогенетические факторы и механизмы, анализируются особенности клинической картины и терапии. Представлены зарубежные и российские научные данные, клинические наблюдения случаев синдрома Гийена – Барре, рассеянного склероза, острого диссеминированного энцефаломиелита, миастении и других аутоиммунных заболеваний, возникших или изменивших свое типичное течение на фоне COVID-19.

Since the onset of the SARS-CoV-2 infection, there has been an increase in the number of reports of patients who have experienced the development of autoimmune neurological disorders. It is assumed that such an increase in the incidence rate may occur due to an abnormal immune-mediated response of the body to the pathogenic impact of SARS-CoV-2. This article discusses the possibility of the influence of SARS-CoV-2 on the onset and exacerbation of the course of autoimmune neurological disorders, possible pathogenetic factors and mechanisms, and analyzes the features of the clinical picture and therapy. The article includes foreign and Russian scientific data and clinical observations of cases of Guillain-Barré syndrome, multiple sclerosis, acute disseminated encephalomyelitis, myasthenia gravis and other autoimmune diseases that have changed their typical course on the background of COVID-19.

COVID-19SARS-CoV-2аутоиммунные неврологические заболеванияCOVID-19SARS-CoV-2autoimmune neurological diseasesИсследование выполнено при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Соглашение № 075-15-2020-901 от 13.11.2020).ReferencesCenter for Systems Science and Engineering // COVID-19 content portal. URL:www.systems.jhu.edu/research/public-health/ncov/ (дата обращения: 09.05.2022). Saad I. COVID-19: breaking down a global health crisis / Saad I. [et al.] // Ann Clin Microbiol Antimicrob. – 2021. Vol.20, №35.Center for Systems Science and Engineering // COVID-19 content portal. URL:www.systems.jhu.edu/research/public-health/ncov/ (дата обращения: 09.05.2022). Saad I. COVID-19: breaking down a global health crisis / Saad I. [et al.] // Ann Clin Microbiol Antimicrob. – 2021. Vol.20, №35.Galea M. Neurological manifestations and pathogenic mechanisms of COVID-19 / Galea M. [et al.] // Neurological Research. – 2022. – Р. 1-12.Galea M. Neurological manifestations and pathogenic mechanisms of COVID-19 / Galea M. [et al.] // Neurological Research. – 2022. – Р. 1-12.Лобзин, Ю.В. COVID-19-ассоциированный педиатрический мультисистемный воспалительный синдром / Ю.В. Лобзин [и др.] // Медицина экстремальных ситуаций. – 2021. – № 2. – С. 13–19.Lobzin YU.V., A.N., Skripchenko N.V., Vil’nic A.A., Bekhtereva M.K., Babachenko I.V. COVID-19-associirovannyj pediatricheskij mul’tisistemnyj vospalitel’nyj sindrom / Lobzin YU.V. [i dr.] // Medicina ekstremal’nyh situacij. – 2021. №2. – S. 13-19. (in Russian).Mahboubi M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches / Mahboubi M. [et al.] // // Reviews in Medical Virology. – 2022. – Р. e2334.Mahboubi M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches / Mahboubi M. [et al.] // // Reviews in Medical Virology. – 2022. – Р. e2334.Manzano G. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis / Manzano G. [et al.] // Neurology Neuroimmunology Neuroinflammation. – 2021. Vol.8, №6. – Р. e1080.Manzano G. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis / Manzano G. [et al.] // Neurology Neuroimmunology Neuroinflammation. – 2021. Vol.8, №6. – Р. e1080.Ariño H. Neuroimmune disorders in COVID-19 / Ariño H. [et al.] // Journal of Neurology. – 2022. – Р. 1-13.Ariño H. Neuroimmune disorders in COVID-19 / Ariño H. [et al.] // Journal of Neurology. – 2022. – Р. 1-13.Molina А.Е. SARS-CoV-2, a new causative agent of Guillain-Barré syndrome? / Molina А.Е. [et al.] // Med Intensiva. – 2022. – Vol.46, № 2. – Р. 110-111. Abu-Rumeileh S. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases / Abu-Rumeileh S. [et al.] // Journal of neurology. 2021. – Vol.268, № 4. – Р. 1133-1170.Molina А.Е. SARS-CoV-2, a new causative agent of Guillain-Barré syndrome? / Molina А.Е. [et al.] // Med Intensiva. – 2022. – Vol.46, № 2. – Р. 110-111. Abu-Rumeileh S. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases / Abu-Rumeileh S. [et al.] // Journal of neurology. 2021. – Vol.268, № 4. – Р. 1133-1170.Dalakas M.C. Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing / Dalakas M.C. // Neurology Neuroimmunology Neuroinflammation. – 2020. – Vol.7, №5.Dalakas M.C. Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing / Dalakas M.C. // Neurology Neuroimmunology Neuroinflammation. – 2020. – Vol.7, №5.Seyede M. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report / Seyede M. [et al.] // J Med Case Rep. – 2022. – Vol.16,№1.Seyede M. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report / Seyede M. [et al.] // J Med Case Rep. – 2022. – Vol.16,№1.Keddie S. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome / Keddie S. // Brain. – 2021. – Vol.144,№2. – Р. 682-693.Keddie S. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome / Keddie S. // Brain. – 2021. – Vol.144,№2. – Р. 682-693.Sriwastava S. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series / Sriwastava S. [et al.] // Journal of the neurological sciences. – 2021. – Vol. 15, №420. – Р. 117263.Sriwastava S. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series / Sriwastava S. [et al.] // Journal of the neurological sciences. – 2021. – Vol. 15, №420. – Р. 117263.Laved A. Neurological associations of SARS-cov-2 infection: a systematic review / Laved A. // CNS Neurol Disord Drug Targets. – 2022. – Vol. 21, №3. – P. 246-258.Laved A. Neurological associations of SARS-cov-2 infection: a systematic review / Laved A. // CNS Neurol Disord Drug Targets. – 2022. – Vol. 21, №3. – P. 246-258.Mohammad А. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review / Mohammad А. [et al.] // Can J Neurol Sci. – 2022. – №1. – P. 1-11.Mohammad А. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review / Mohammad А. [et al.] // Can J Neurol Sci. – 2022. – №1. – P. 1-11.Finsterer J. Guillain-Barré syndrome is immunogenic in SARS-CoV-2 infected / Finsterer J. [et al.] // J Med Virol. 2022. – Vol. 94, №1. – P. 22-23.Finsterer J. Guillain-Barré syndrome is immunogenic in SARS-CoV-2 infected / Finsterer J. [et al.] // J Med Virol. 2022. – Vol. 94, №1. – P. 22-23.Marie I. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature / Marie I. [et al.] // British Journal of Dermatology. 2006. – №4. – Р. 714-721.Marie I. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature / Marie I. [et al.] // British Journal of Dermatology. 2006. – №4. – Р. 714-721.Hoepner R. Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with multiple sclerosis or neuromyelitis optica spectrum disorder? / Hoepner R. [et al.] // CNS Neurosci Ther. – 2022. – Vol.28, №6. – P.971-973.Hoepner R. Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with multiple sclerosis or neuromyelitis optica spectrum disorder? / Hoepner R. [et al.] // CNS Neurosci Ther. – 2022. – Vol.28, №6. – P.971-973.Xia H. Evasion of type I interferon by SARS-CoV-2 / Xia H. [et al.] // Cell reports. – 2020. – Vol. 33, №1. – Р. 108234.Xia H. Evasion of type I interferon by SARS-CoV-2 / Xia H. [et al.] // Cell reports. – 2020. – Vol. 33, №1. – Р. 108234.Sormani M. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France / Sormani M. [et al.] // Annals of Clinical and Translational Neurology. – 2021. – Vol.8, №8. Р. 1738-1744.Sormani M. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France / Sormani M. [et al.] // Annals of Clinical and Translational Neurology. – 2021. – Vol.8, №8. Р. 1738-1744.Finsterer J. SARS-CoV-2 triggered relapse of multiple sclerosis / Finsterer J. // Clin Neurol Neurosurg. – 2022. №215. – Р.207-210.Finsterer J. SARS-CoV-2 triggered relapse of multiple sclerosis / Finsterer J. // Clin Neurol Neurosurg. – 2022. №215. – Р.207-210.Alroughani R. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East / Alroughani R. [et al.] // J Clin Neurosci. – 2022. – №99. – P. 311-316.Alroughani R. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East / Alroughani R. [et al.] // J Clin Neurosci. – 2022. – №99. – P. 311-316.Wang Y. SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature / Wang Y. [et al.] // Journal of Neurology. – 2021. – Р.1-22.Wang Y. SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature / Wang Y. [et al.] // Journal of Neurology. – 2021. – Р.1-22.Wang C. Assessment and management of acute disseminated encephalomyelitis (ADEM) in the pediatric patient / Wang C. // Pediatric Drugs. – 2021. – Vol.23(3);213-221.Wang C. Assessment and management of acute disseminated encephalomyelitis (ADEM) in the pediatric patient / Wang C. // Pediatric Drugs. – 2021. – Vol.23(3);213-221.Esmaeili S. Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report / Esmaeili S. [et al.] // Ann Med Surg (Lond). – 2022. – №77. – P. 103511.Esmaeili S. Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report / Esmaeili S. [et al.] // Ann Med Surg (Lond). – 2022. – №77. – P. 103511.Gilhus N.E. Myasthenia gravis: subgroup classification and therapeutic strategies / Gilhus N.E., Verschuuren J. // Lancet Neurol. 2015; Vol.14, №10. – Р. 1023-36.Gilhus N.E. Myasthenia gravis: subgroup classification and therapeutic strategies / Gilhus N.E., Verschuuren J. // Lancet Neurol. 2015; Vol.14, №10. – Р. 1023-36.Baig A.M. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms / Baig A.M. [et al.] // ACS Chem Neurosci. – 2020. – Vol.11, №7. – Р.995-998.Baig A.M. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms / Baig A.M. [et al.] // ACS Chem Neurosci. – 2020. – Vol.11, №7. – Р.995-998.Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol.40, №6. – Р. 1577-89.Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol.40, №6. – Р. 1577-89.Thiruppathi M. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis / Thiruppathi M. [et al.] // Clin Immunol. – 2012. Vol.145, №3. – Р. 209-2.Thiruppathi M. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis / Thiruppathi M. [et al.] // Clin Immunol. – 2012. Vol.145, №3. – Р. 209-2.Gunes H. What chances do children have against COVID-19? Is the answer hidden within the thymus? / Gunes H. [et al.] // European journal of pediatrics. – 2021. – Vol.180, №3. – Р. 983-986.Gunes H. What chances do children have against COVID-19? Is the answer hidden within the thymus? / Gunes H. [et al.] // European journal of pediatrics. – 2021. – Vol.180, №3. – Р. 983-986.Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W., Su B., Pang L, Qiao L. // Cell Mol Immunol. – 2020. – Vol.17, №6. – Р. 650-652.Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W., Su B., Pang L, Qiao L. // Cell Mol Immunol. – 2020. – Vol.17, №6. – Р. 650-652.Quin C. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China / Quin C., Zhou L., Hu Z. // Clin Infect Dis. – 2020. – Vol.71, №15. – Р. 762-768.Quin C. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China / Quin C., Zhou L., Hu Z. // Clin Infect Dis. – 2020. – Vol.71, №15. – Р. 762-768.Muir R. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome / Muir R., Osbourn M., Dubois A.V. // Am J Respir Crit Care Med. – 2016. – Vol.193, №4. – Р. 407-16.Muir R. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome / Muir R., Osbourn M., Dubois A.V. // Am J Respir Crit Care Med. – 2016. – Vol.193, №4. – Р. 407-16.Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S. // J Neurol. – 2021. – Vol.268, №8. – Р. 2690-2696.Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S. // J Neurol. – 2021. – Vol.268, №8. – Р. 2690-2696.Brossard-Barbosa N. Seropositive ocular myasthenia gravis developing shortly after COVID-19 infection: report and review of the literature / Brossard-Barbosa N. [et al.] // J Neuroophthalmol. – 2022.Brossard-Barbosa N. Seropositive ocular myasthenia gravis developing shortly after COVID-19 infection: report and review of the literature / Brossard-Barbosa N. [et al.] // J Neuroophthalmol. – 2022.Алексеева, Т.М. Дебют генерализованной миастении после перенесенной новой коронавирусной инфекции (COVID-19) / Т.М. Алексеева [и др.] // Журнал инфектологии. – 2021. – Т.13, № 4. – С. 127–132.Alekseeva T.M., Isabekova P.SH., Topuzova M.P., Skripchenko N.V. Debyut generalizovannoj miastenii posle perenesennoj novoj koronavirusnoj infekcii (COVID-19) / Alekseeva T.M. [i dr.] // ZHurnal infektologii. – 2021. – T.13, №4. – S. 127-132. (in Russian).Jakubíkova M. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival / Jakubíkova M., Tyblova M., Tesar A., Horakova M. // Eur J Neurol. – 2021. – Vol.28, №10. – Р. 3418-3425.Jakubíkova M. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival / Jakubíkova M., Tyblova M., Tesar A., Horakova M. // Eur J Neurol. – 2021. – Vol.28, №10. – Р. 3418-3425.Kim Y. Outcomes in myasthenia gravis patients: analysis from electronic health records in the United States / Kim Y. [et al.] // Front Neurol. – 2022.Kim Y. Outcomes in myasthenia gravis patients: analysis from electronic health records in the United States / Kim Y. [et al.] // Front Neurol. – 2022.Muppidi S. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) / Muppidi S. [et al.] // Lancet Neurol. – 2020. – Vol.19, №12. – Р. 970-971.Muppidi S. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) / Muppidi S. [et al.] // Lancet Neurol. – 2020. – Vol.19, №12. – Р. 970-971.Emamikhah M. Opsoclonus-myoclonussyndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature / Emamikhah M. [et al.] // Journal of neurovirology. – 2021. – Vol.1, №9.Emamikhah M. Opsoclonus-myoclonussyndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature / Emamikhah M. [et al.] // Journal of neurovirology. – 2021. – Vol.1, №9.Urrea-Mendoza E. Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) associated with SARS-CoV-2 infection: post-infectious neurological complication with benign prognosis / UrreaMendoza E., Okafor K. // J Neurovirol. – 2021. – Vol.11, №7.Urrea-Mendoza E. Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) associated with SARS-CoV-2 infection: post-infectious neurological complication with benign prognosis / UrreaMendoza E., Okafor K. // J Neurovirol. – 2021. – Vol.11, №7.Fernandes J. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2 / Fernandes J., Puhlmann P. // Journal of Neurovirology. – 2021. – Vol.1, №3.Fernandes J. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2 / Fernandes J., Puhlmann P. // Journal of Neurovirology. – 2021. – Vol.1, №3.Roman G. Acute transverse myelitis (ATM. clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222) / Roman G., Gracia F. // Frontiers in immunology. – 2021. – Vol.12, №879.Roman G. Acute transverse myelitis (ATM. clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222) / Roman G., Gracia F. // Frontiers in immunology. – 2021. – Vol.12, №879.

The authors declare that there are no conflicts of interest present.